No­vo Nordisk set­tles in­sulin pric­ing suit for $100M

No­vo Nordisk, one of the world’s top three man­u­fac­tur­ers of in­sulin, agreed to pay $100 mil­lion to set­tle a 2017 in­vestor suit that al­leged the com­pa­ny failed to dis­close that it was un­der the same pric­ing pres­sures as its com­peti­tors.

No­vo said in a state­ment on Fri­day the set­tle­ment was reached af­ter a vol­un­tary me­di­a­tion process and re­solves claims brought on by in­vestors for al­leged vi­o­la­tions of US se­cu­ri­ties laws. The com­pa­ny said the set­tle­ment con­tains no ad­mis­sion of li­a­bil­i­ty, wrong­do­ing or re­spon­si­bil­i­ty by any of the de­fen­dants.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters